Switch to Health Care Professionals
Print PagePulmozyme Access Solutions—Committed to Helping You Access Pulmozyme (dornase alfa)
- Useful Links
- Forms and Documents
- What's New?
- Full Pulmozyme Access Solutions website to come later this year.
- Medicare Appointment of Representative (AOR)
- Find out more about Genentech Access Solutions™
- Learn about co-pay assistance
Understanding how to access and pay for your medication can be challenging. Pulmozyme Access Solutions is here to help you understand your options and the process.
Coverage and Reimbursement
Pulmozyme Access Solutions helps resolve specific access and reimbursement issues for individual patients every day. Our specialists are passionate about helping you access Pulmozyme and exploring every appropriate solution to coverage or reimbursement issues.
Patient Assistance
To learn more about our patient assistance programs, please click on the button that applies to you.
- I’m uninsured or my health insurance denied my coverage
- I have health insurance and need help with my co-pay*
Informational Resources
We all know it’s important to have the right information at your fingertips. With this in mind, we’ve compiled a list of informational resources you may find useful.
Pulmozyme (dornase alfa) Important Safety Information
Indications
Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.
Pulmozyme Safety Information
The most common adverse events reported include voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis. Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product. Pulmozyme should be used in conjunction with standard therapies for CF.
Because of the limited experience with the administration of Pulmozyme to patients younger than 5 years of age, its use should be considered only for those patients in whom there is a potential for benefit in pulmonary function or in risk of respiratory tract infection.
Please see full Prescribing Information for Pulmozyme, including Important Safety Information.
*Co-pay refers to a cost-sharing arrangement in which members of health insurance plans pay a specified charge for a product or service, such as a prescription or an office visit. Members are typically responsible for this payment at the time of service.
Privacy information: Any information submitted to Pulmozyme Access Solutions will remain confidential and will not be used for promotional purposes.
If you would like to learn more about protecting the privacy of personal health information, please go to the U.S. Department of Health & Human Services website at www.hhs.gov/ocr/hipaa/.
